Format

Send to

Choose Destination
Clin Lymphoma Myeloma Leuk. 2011 Jun;11 Suppl 1:S46-8. doi: 10.1016/j.clml.2011.04.003. Epub 2011 May 7.

Allogeneic stem cell transplantation for myelodysplastic syndromes: critical for cure?

Author information

1
Department of Tumor Immunology, Nijmegen Centre for Life Sciences, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. deWitte@ncmls.ru.nl

Abstract

Allogeneic stem cell transplantation (SCT) is the treatment of choice for young patients (age ≤ 55 years) with myelodysplastic syndromes (MDS) characterized by poor-risk or intermediate-risk cytogenetics, who have a histocompatible related or unrelated donor. For patients who lack an human leukocyte antigen-compatible donor, autologous SCT, or chemotherapy may be good alternatives for those with MDS and with good-risk cytogenetic characteristics. Iron toxicity is an underestimated cause of hematopoietic stem cell transplantation (HSCT) treatment-related mortality. The pathogenesis, diagnosis, and monitoring of iron-induced organ damage are currently topics of investigation. Prospective studies on the prevention or treatment of iron toxicity before HSCT and/or after HSCT are necessary.

PMID:
22035747
DOI:
10.1016/j.clml.2011.04.003
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center